Article
Endocrinology & Metabolism
Daniela Annibali, Sarah-Maria Fendt
Summary: The study demonstrates the transition of PHGDH to the nucleus following nutrient stress, impacting the activity of c-Jun and contributing to sustained cancer cell proliferation.
Article
Biochemistry & Molecular Biology
Fu-Ying Zhao, Qi Zhang, Jia-Mei Wang, Jing-Yi Jiang, Ling-Yue Huyan, Bao-Qin Liu, Jing Yan, Chao Li, Hua-Qin Wang
Summary: Ovarian cancer is a highly lethal gynecologic malignancy, often diagnosed late with high recurrence rates. The upregulation of BAG3 and its regulation of GALNT10 have been shown to facilitate CSC-like properties of ovarian cancer cells and impact disease-free survival in patients. Additionally, BAG3 epigenetically regulates GALNT10 via WDR5 to promote CSCs in platin-resistant ovarian cancers, providing potential therapeutic targets.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Pei Du, Xueyuan Xu, Ying Wang
Summary: This study provides new insights into the role of circRNAs in the mechanism of cisplatin-resistance in ovarian cancer. Hsa_circRNA_0000585 may be a promising therapeutic target for enhancing the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Review
Biochemistry & Molecular Biology
Jie Mo, Huifang Liang, Chen Su, Pengcheng Li, Jin Chen, Bixiang Zhang
Summary: DDX3X, a member of the DEAD-box helicase family, plays critical roles in various stages of RNA metabolism and is implicated in the progression of diseases, especially cancer. Research has gradually unveiled the diverse functions of DDX3X in cancer biology, providing insights into its involvement in tumorigenesis and progression.
Article
Multidisciplinary Sciences
Matteo Rossi, Patricia Altea-Manzano, Margherita Demicco, Ginevra Doglioni, Laura Bornes, Marina Fukano, Anke Vandekeere, Alejandro M. Cuadros, Juan Fernandez-Garcia, Carla Riera-Domingo, Cristina Jauset, Melanie Planque, H. Furkan Alkan, David Nittner, Dongmei Zuo, Lindsay A. Broadfield, Sweta Parik, Antonino Alejandro Pane, Francesca Rizzollo, Gianmarco Rinaldi, Tao Zhang, Shao Thing Teoh, Arin B. Aurora, Panagiotis Karras, Ines Vermeire, Dorien Broekaert, Joke Van Elsen, Maximilian M. L. Knott, Martin F. Orth, Sofie Demeyer, Guy Eelen, Lacey E. Dobrolecki, Ayse Bassez, Thomas Van Brussel, Karl Sotlar, Michael T. Lewis, Harald Bartsch, Manfred Wuhrer, Peter van Veelen, Peter Carmeliet, Jan Cools, Sean J. Morrison, Jean-Christophe Marine, Diether Lambrechts, Massimiliano Mazzone, Gregory J. Hannon, Sophia Y. Lunt, Thomas G. P. Grunewald, Morag Park, Jacco van Rheenen, Sarah-Maria Fendt
Summary: The loss of phosphoglycerate dehydrogenase (PHGDH) has been found to increase cancer metastasis. Heterogeneous or low expression of PHGDH in primary tumors of breast cancer patients is associated with decreased metastasis-free survival time. Loss of PHGDH activates the hexosamine-sialic acid pathway through its interaction with the glycolytic enzyme phosphofructokinase, leading to increased cell migration and invasion.
Article
Pharmacology & Pharmacy
Federica Foglietta, Manuela Macri, Patrizia Panzanelli, Andrea Francovich, Gianni Durando, Francesca Garello, Enzo Terreno, Loredana Serpe, Roberto Canaparo
Summary: Ovarian cancer is a deadly disease with high mortality, frequent relapses, and drug resistance. Sonodynamic therapy, which combines a sonosensitizer and low-intensity ultrasound, is a promising approach for cancer treatment. This research investigates the use of the chemotherapeutic drug Doxorubicin as a sonosensitizer to induce cell death in ovarian cancer cells and prevent recurrence. The results show that this sonodynamic therapy with Doxorubicin is effective and operates through a ROS-dependent mechanism and immune sensitization based on the activation of the ICD pathway.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2023)
Article
Multidisciplinary Sciences
Marc Hennequart, Christiaan F. Labuschagne, Mylene Tajan, Steven E. Pilley, Eric C. Cheung, Nathalie M. Legrave, Paul C. Driscoll, Karen H. Vousden
Summary: Cancer cells grown under physiological metabolite levels show decreased sensitivity to serine withdrawal. Limiting serine availability leads to increased de novo serine synthesis and utilization of hypoxanthine to support purine synthesis. This study enhances our understanding of serine metabolism under physiologically relevant nutrient conditions and suggests potential interventions for enhancing therapeutic response to dietary serine/glycine limitation.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Evelin Pellegrini, Giuseppina Multari, Davide Vecchiotti, Francesca Zazzeroni, Maria Condello, Stefania Meschini, Francesca Romana Gallo
Summary: This study evaluated the chemosensitizing effect of the natural compound VOA in drug-resistant ovarian and colon cancer cell lines. The results showed that the combination of VOA with PTX or DOX induced apoptotic cell death and was effective only on drugs known to be substrates of P-gp. These findings may have implications for improving the efficacy of chemotherapy in ovarian and colon cancer.
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Liliang Shen, Junfeng Zhang, Zongtai Zheng, Fuhan Yang, Shenghua Liu, Yuan Wu, Yifan Chen, Tianyuan Xu, Shiyu Mao, Yang Yan, Wei Li, Wentao Zhang, Xudong Yao
Summary: The study revealed that PHGDH upregulates SLC7A11 expression via interaction with PCBP2, inhibiting ferroptosis and promoting malignant progression of BCa. The findings suggest that NCT-502 could be a potential therapeutic strategy for BCa.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Editorial Material
Biochemistry & Molecular Biology
Duygu Kuzuoglu-Ozturk
Summary: Recent research reveals a novel role of PHGDH, an enzyme in the de novo serine synthesis pathway, as a regulator of mitochondrial translation and tumor progression in liver cancer.
Article
Oncology
Daniel Hopkins, Hector Sanchez, Brent Berwin, Ivy Wilkinson-Ryan
Summary: The study demonstrates that treatment with cisplatin leads to an increase in monocytes within tumor bearing mice ascites, which in turn enhances IFN-gamma expression in CD8(+) T-cells and activates splenocytes to release higher levels of IFN-gamma when incubated with dendritic cells and tumor antigen. Additionally, cisplatin treatment induces activation markers on T-cells and monocyte/macrophages, while reducing levels of IL-10, IL-6, and VEGF in the cell free ascites of mice. Further investigation in humans is needed to determine the potential role of monocyte directed therapy in combination with other treatment modalities.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jaemoo Chun
Summary: Isoalantolactone, a compound derived from Inula helenium L., has been identified as a potential glycolysis inhibitor to overcome cisplatin resistance in ovarian cancer. It effectively targets key glycolytic enzymes and enhances sensitivity to cisplatin-induced apoptosis. In vivo studies demonstrate its ability to suppress tumor growth in cisplatin-resistant ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Guan-Nan Li, Xue-Jiao Zhao, Zhen Wang, Meng-Shi Luo, Shen-Nan Shi, Dan-Mei Yan, Hua-Yi Li, Jia-Hao Liu, Yang Yang, Jia-Hong Tan, Ze-Yu Zhang, Ru-Qi Chen, Hui-Ling Lai, Xiao-Yuan Huang, Jian-Feng Zhou, Ding Ma, Yong Fang, Qing-Lei Gao
Summary: The research revealed a new role for elaiophylin in inducing excessive endoplasmic reticulum stress, ER-derived cytoplasmic vacuolization, and consequent paraptosis by hyperactivating the MAPK pathway in cancer cells. Elaiophylin was found to overcome drug resistance by triggering paraptosis in tumor-bearing mouse models resistant to platinum, taxane, or PARPi, suggesting its potential as a therapeutic strategy for refractory ovarian cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Biotechnology & Applied Microbiology
Disha Mittal, Largee Biswas, Anita Kamra Verma
Summary: The study aimed to sensitize cisplatin-resistant ovarian cancer cells towards cisplatin using cisplatin-loaded nanostructured lipid carriers. The results showed that the synthesized cisplatin-loaded nanostructured lipid carriers successfully enhanced the sensitivity of the resistant cancer cells by modifying reactive oxygen species levels and increasing apoptosis in the cells.
Review
Oncology
Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang
Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.